Alliancebernstein L.P. Sells 10,157 Shares of NeoGenomics, Inc. (NASDAQ:NEO)

Alliancebernstein L.P. lowered its holdings in NeoGenomics, Inc. (NASDAQ:NEO) by 6.0% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 160,340 shares of the medical research company’s stock after selling 10,157 shares during the period. Alliancebernstein L.P. owned approximately 0.12% of NeoGenomics worth $2,642,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently made changes to their positions in NEO. Norges Bank acquired a new stake in NeoGenomics during the fourth quarter worth approximately $6,273,000. Loomis Sayles & Co. L P lifted its position in shares of NeoGenomics by 48.4% during the 4th quarter. Loomis Sayles & Co. L P now owns 1,791,792 shares of the medical research company’s stock valued at $29,528,000 after acquiring an additional 584,502 shares during the period. Segall Bryant & Hamill LLC grew its holdings in shares of NeoGenomics by 11.6% during the 4th quarter. Segall Bryant & Hamill LLC now owns 2,113,822 shares of the medical research company’s stock worth $34,836,000 after purchasing an additional 220,415 shares in the last quarter. Vanguard Group Inc. raised its stake in NeoGenomics by 1.4% in the fourth quarter. Vanguard Group Inc. now owns 14,239,887 shares of the medical research company’s stock valued at $234,673,000 after purchasing an additional 195,793 shares in the last quarter. Finally, KLP Kapitalforvaltning AS acquired a new position in NeoGenomics in the fourth quarter valued at about $453,000. Institutional investors and hedge funds own 98.50% of the company’s stock.

Analyst Ratings Changes

NEO has been the subject of several analyst reports. Bank of America dropped their target price on shares of NeoGenomics from $19.00 to $16.00 and set a “neutral” rating for the company in a research report on Wednesday, February 19th. Needham & Company LLC cut their target price on NeoGenomics from $19.00 to $18.00 and set a “buy” rating for the company in a research note on Wednesday, February 19th. Benchmark lowered NeoGenomics from a “buy” rating to a “hold” rating in a research note on Monday, January 13th. Piper Sandler dropped their price objective on NeoGenomics from $21.00 to $18.00 and set an “overweight” rating for the company in a research report on Wednesday, February 26th. Finally, The Goldman Sachs Group decreased their target price on NeoGenomics from $20.00 to $18.00 and set a “buy” rating on the stock in a research report on Tuesday, January 28th. Two research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $19.60.

NeoGenomics Stock Performance

NeoGenomics stock opened at $9.50 on Wednesday. The business has a 50 day moving average of $10.42 and a 200-day moving average of $13.71. The company has a market capitalization of $1.22 billion, a P/E ratio of -15.32 and a beta of 1.41. NeoGenomics, Inc. has a 1 year low of $8.05 and a 1 year high of $19.12. The company has a debt-to-equity ratio of 0.38, a current ratio of 1.98 and a quick ratio of 1.91.

NeoGenomics (NASDAQ:NEO) last announced its quarterly earnings results on Tuesday, February 18th. The medical research company reported ($0.02) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.03 by ($0.05). The business had revenue of $172.00 million during the quarter, compared to analyst estimates of $173.40 million. NeoGenomics had a negative net margin of 11.92% and a negative return on equity of 2.10%. On average, equities research analysts predict that NeoGenomics, Inc. will post -0.2 earnings per share for the current year.

NeoGenomics Company Profile

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.